Interleukin 1 and poly(rI).poly(rC) induce production of a hybridoma growth factor by human fibroblasts.
Cultures of normal diploid fibroblasts and of a human osteosarcoma cell line (MG-63) are shown to be able to produce a factor which promotes the growth of B cell hybridomas (hybridoma growth factor, HGF). The induction is stimulated by treatment of the cells with interleukin 1 (IL 1) (alpha or beta) or polyriboinosinic-polyribocytidylic acid [poly(rI).poly(rC)]. Combined treatment with cycloheximide and actinomycin D also stimulates production and enhances production induced by IL 1 or poly(rI).poly(rC). Extremely small doses of IL 1 (0.1 units/ml) are active as inducer of HGF. Also, under optimal conditions the yield of HGF can attain as much as 10(4) units/ml. Tumor necrosis factor (TNF-alpha), which otherwise shares various properties with IL 1, is a weak inducer of HGF. Although there is a superficial resemblance between induction of HGF and that of interferon-beta, the two activities are serologically distinct and conditions for their induction are quite different. In fact, conditions for induction of HGF are indistinguishable from those described for the induction of the mRNA of the so-called 26-kDa protein (also known as interferon-beta 2). Finally, the HGF derived from IL 1- or poly(rI).poly(rC)-treated fibroblasts is serologically not distinguishable from that produced by mitogen-stimulated peripheral blood leukocytes.
D000818:Animals; D001402:B-Lymphocytes; D001688:Biological Products / Q000494:pharmacology; D002460:Cell Line; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology; D006224:Cricetinae; D003412:Cricetulus; D003513:Cycloheximide / Q000494:pharmacology; D016207:Cytokines; D003609:Dactinomycin / Q000494:pharmacology; D005260:Female; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism; D006133:Growth Substances / Q000096:biosynthesis*; D006801:Humans; D006825:Hybridomas / Q000187:drug effects*; D007370:Interferon Type I / Q000096:biosynthesis; D007375:Interleukin-1 / Q000494:pharmacology*; D007700:Kinetics; D007739:L Cells / Q000187:drug effects / Q000378:metabolism; D007962:Leukocytes / Q000378:metabolism; D051379:Mice; D012516:Osteosarcoma / Q000473:pathology; D010053:Ovary; D011070:Poly I-C / Q000494:pharmacology*; D012867:Skin
D001688:Biological Products; D016207:Cytokines; D006133:Growth Substances; D007370:Interferon Type I; D007375:Interleukin-1; D003208:Concanavalin A; D003609:Dactinomycin; D003513:Cycloheximide; D011070:Poly I-C